Omega ‘not aware of reason’ for latest share surge

Alva-based Omega Diagnostics Group said it is “not aware of any material reason” for latest 18% the increase in its share price on Wednesday.

Shares of Omega have risen exponentially in the past two months amid news it “CE-Marked Mologic Ltd’s first generation ELISA antibody test for COVID-19.”

On Wednesday, Omega said: “As previously announced the company continues to work with its partner Mologic Ltd with regards its first generation ELISA antibody test for COVID-19 and also with the UK Rapid Test Consortium, which is jointly developing, and will manufacture, a Point-of-Care COVID-19 lateral flow antibody test.

“In respect of both these opportunities the company will keep the market informed as matters develop.

“In a Sky News interview earlier today, the introduction referred to the Consortium being able to make 50m tests a year, a figure also referred to in a newspaper article published on 26 April 2020.

“This is not a figure that relates to the potential output from Omega and its manufacturing facilities alone.”

About the Author

Mark McSherry
Dalriada Media LLC sites are edited by veteran news journalist Mark McSherry, a former staff editor and reporter with Reuters, Bloomberg and major newspapers including the South China Morning Post, London's Sunday Times and The Scotsman. McSherry's journalism has also appeared in The Washington Post, The Guardian, The Independent, The New York Times, London's Evening Standard and Forbes. McSherry is also a professor of journalism and communication arts in universities and colleges in New York City. Scottish-born McSherry has an MBA from the University of Edinburgh and a Certificate in Global Affairs from New York University.